MedTrace Logo

PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors

NCT00763750 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-02-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.

Conditions

Interventions

DRUG

PPX +TMZ+XRT

PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)

Sponsors & Collaborators

  • Rhode Island Hospital

    collaborator OTHER

  • MaineHealth

    collaborator OTHER

  • howard safran

    lead OTHER

Principal Investigators

  • Howard Safran, MD · BrUOG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-06-30
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00763750 on ClinicalTrials.gov